Theradiag Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Simon Daviere

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	1.5yrs

Actualizaciones recientes de la dirección

Recent updates

Slammed 26% Theradiag SA (EPA:ALTER) Screens Well Here But There Might Be A Catch

Oct 04

Theradiag (EPA:ALTER) Might Have The Makings Of A Multi-Bagger

Oct 03

Theradiag (EPA:ALTER) Is Carrying A Fair Bit Of Debt

Oct 26

CEO

Simon Daviere (39 yo)

less than a year

Permanencia

Mr. Simon Davière is Chief Executive Officer of Theradiag SA from March 01, 2023 and also serves as its General Manager since 2023. He holds an engineering degree in Biological Engineering from the Univers...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian Policard	Independent Chairman	less than a year	sin datos	sin datos
Larry Abensur	Director	1.6yrs	sin datos	sin datos
Thierry Paper	Director	1.6yrs	sin datos	sin datos
Jacques Azancot	Independent Director	1.5yrs	sin datos	sin datos

1.5yrs

Permanencia media

Junta con experiencia: La junta directiva de ALTER no se considera experimentada (1.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Theradiag Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Theradiag Announces Executive Changes

Theradiag Announces Board Changes

Recent updates

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Slammed 26% Theradiag SA (EPA:ALTER) Screens Well Here But There Might Be A Catch

Investor sentiment deteriorates as stock falls 26%

Theradiag (EPA:ALTER) Might Have The Makings Of A Multi-Bagger

Forecast breakeven date pushed back to 2024

Theradiag SA to Report First Half, 2023 Results on Sep 18, 2023

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.011 loss in 1H 2021)

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Theradiag Announces the Launch of ez-Track, A Point-Of-Care Testing Solution for Therapeutic Drug Monitoring

THERADIAG Announces the Launch of Two New i-Tracker® Kits

Less than half of directors are independent

Theradiag Announces Executive Changes

Full year 2021 earnings: Revenues in line with analyst expectations

THERADIAG Announces the Launch of 4 New i-Tracker® Kits and the Validation of a New Parameter in the United States

Price target decreased to €2.48

Theradiag (EPA:ALTER) Is Carrying A Fair Bit Of Debt

First half 2021 earnings released: €0.011 loss per share

Theradiag Announces the Launch of HUMABDIAG

Full year 2020 earnings released

New 90-day low: €2.42

Investor sentiment deteriorated over the past week

THERADIAG Signs a Contract to Supply ORGENTEC With Quality Control Reagents Called Alegria® Check

Price target raised to €2.95

Theradiag Announces CE Marking for Four New I-Tracker Test Kits for Biotherapy Monitoring

Investor sentiment improved over the past week

Theradiag SA to Report Fiscal Year 2020 Final Results on Mar 22, 2021

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day high: €3.30

Theradiag Announces Board Changes

Theradiag Launches an Antigen Test in France to Detect Covid-19 in Less Than Fifteen Minutes

New 90-day low - €1.84

Price target raised to €1.95

CEO

Permanencia

Miembros de la Junta

Permanencia media